Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07699328RecruitingPhase 1/Phase 2
Study of VRN110755 for EGFR-mutant lung cancer
This trial tests a new oral targeted therapy (VRN110755) for people with EGFR-mutant lung cancer. It is for those whose cancer has advanced or spread, and who either have not been treated yet or who stopped responding to previous EGFR pills.
Bedford Park, South AustraliaAges 18 years+ - NCT07699185RecruitingPhase 2
Immunotherapy plus chemoradiation before surgery for esophageal cancer
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Wuhan, HubeiAges 18–75 - NCT06647901RecruitingPhase 1/Phase 2
ICG dye imaging for giant cell tumor surgery
This trial uses a special dye (ICG) and a camera to help surgeons see the tumor better during surgery for giant cell tumors of bone in the arms or legs. The goal is to remove all of the tumor while saving as much healthy bone as possible.
Beijing, Beijing MunicipalityAges 18–65 - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT04593589RecruitingPhase 1
Stem cell transplant to protect salivary function after oral cancer
This Phase 1 study tests whether transplanting stem cells into the submandibular gland can help restore saliva function after surgery and radiation for oral cavity squamous cell cancer. You may be considered because you recently had tumor removal and radiation aimed at the neck area, which can damage salivary glands.
GroningenAges 18 years+ - NCT07695012RecruitingEarly Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
RawalpindiAges 5–50 - NCT07691606RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has come back
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
Los Angeles, CaliforniaAges 18 years+ - NCT07694375RecruitingPhase 2
Eye drop study to protect corneal cells after cataract surgery
This trial tests an eye drop called CA201A to see if it can prevent loss of cells in the clear front layer of the eye (the cornea) after cataract surgery. The drop contains ascorbic acid, a form of vitamin C, and is given before and after the procedure to help protect the eyesight.
Deakin, Australian Capital TerritoryAges 18–85 - NCT07689643RecruitingEarly Phase 1
Radioactive drug plus immunotherapy for FAP-positive lung cancer
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Wuhan, HubeiAges 18 years+ - NCT07692152RecruitingPhase 3
Immunotherapy vs. chemo for MS anal cancer trial
This trial tests sintilimab (a type of immunotherapy) against mitomycin plus chemotherapy with radiation for anal cancer that hasn't spread. It aims to find a better treatment with fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT05806580RecruitingPhase 4
Second relma-cel infusion for returning B-cell lymphoma
This trial looks at giving a second dose of relma-cel (a type of CAR-T therapy) for B-cell lymphoma that came back or did not fully respond after the first treatment. It may help shrink tumors again, but it requires that side effects from the first treatment and pre-chemo are mostly gone and that you meet infection and blood-test safety checks.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05348213RecruitingPhase 2
Targeted drugs plus R-ICE chemo for relapsed lymphoma
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07680816Recruiting
Study of gamma delta T cells in critically ill patients
This study looks at a type of immune cell called gamma delta T cells in patients who are very sick in the ICU, including those with and without sepsis. The goal is to understand how these cells work differently in these patients, which could help find better treatments.
Wuhan, Outside of the USAges 18–80 - NCT07682831Recruiting
Studying skin biopsies with advanced microscopy
This trial uses a special microscope to look at skin biopsy samples in new ways. It may help doctors understand skin conditions better without needing extra procedures.
Victor, New YorkAges Any age - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Beverly Hills, CaliforniaAges 18 years+ - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25 - NCT06598202RecruitingPhase 1/Phase 2
Nasal Drop Therapy for ALS
This trial tests a nasal drop made from tiny cell particles (extracellular vesicles) for ALS. The goal is to see if it's safe and if it can slow down the disease. It may be an option if your ALS is in the early to moderate stage.
Beijing, Beijing MunicipalityAges 18–80 - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07677124Recruiting
AI analysis of skin images for basal cell carcinoma risk
This study uses artificial intelligence to analyze magnified skin images of basal cell carcinoma to predict the cancer's subtype and risk classification. It aims to improve diagnosis and treatment planning without additional procedures.
Istanbul, IstanbulAges birth–100 years - NCT07680257RecruitingEarly Phase 1
CLDN18.2 CAR T cells for advanced solid tumors
This trial tests a new treatment called CLDN18.2 CAR T cells in people with advanced solid tumors that have a specific marker (CLDN18.2). It aims to see if it is safe and works against cancers that have not responded to standard treatments.
Hefei, AnhuiAges 18–75 - NCT06667154RecruitingPhase 2
Low-dose nivolumab plus chemo for early lung cancer
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
São José do Rio Preto, São PauloAges 18 years+ - NCT07677787Recruiting
PET/CT imaging for small cell lung cancer
This trial uses a special PET/CT scan to look for a protein called DLL3 in small cell lung cancer. The scan may help doctors better see and understand the cancer. You may be able to join if you have suspected or confirmed small cell lung cancer and certain blood markers are high.
Xiamen, FujianAges 18–80
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.